Summary of talimogene laherparepvec responses by lesion-type
| Overall tumor response | Overall lesion-type response | |||
|---|---|---|---|---|
| Any | OR | CR | Yes | |
| n (%) | n (%) | n (%) | n (%) | |
| Any | 37 (100) | 14 (37.8) | 8 (21.6) | 15 (40.5) |
| At least 1 baseline uninjected lesion | 35 (100) | 12 (34.3) | 6 (17.1) | 13 (37.1) |
| Baseline uninjected non-visceral only | 23 (100) | 10 (43.5) | 5 (21.7) | 11 (47.8) |
| At least 1 visceral lesion at baseline | 12 (100) | 2 (16.7) | 1 (8.3) | 2 (16.7) |
Denominator is the total number of patients in corresponding patient lesion-type subgroup
Objective response (OR), and complete response (CR) as per investigator-reported responses. Overall lesion response was reported as the proportion of patients with a ≥ 30 % decrease in overall lesion burden. OR was evaluated by modified RECIST.
Overall lesion type response: max decrease ≥ 30 % in overall lesion-type burden from baseline in patient lesion-type subgroup and in total tumor burden for “Any”
All patients received at least one dose of talimogene laherparepvec